96 completed. 96 Phase 1, 45 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 96 | Completed 96 |
| Phase 2 | 45 | Completed 45 |
Follow Revlimid: new trials by email Literature Review of Revlimid trials Research Report on Revlimid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies Romidepsin, Lenalidomide, CC-486 (5-azacitidine) - Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2020-12-17 | 2026-10-14 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer Romidepsin, Azacitidine, nab-Paclitaxel - Pancreas Cancer, Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | GWT-TUD GmbH | 75 | 2020-05-25 | 2025-09-30 |
| Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma Ibrutinib, Lenalidomide, Dexamethasone - Refractory Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Completed | Alliance Foundation Trials, LLC. | 14 | 2019-08-29 | 2026-01-06 |
| Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma Lenalidomide 15mg, Brentuximab Vedotin 1.8 mg/Kg - Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral | Phase 1 | Completed | Peter MacCallum Cancer Centre, Australia | 6 | 2018-08-30 | 2022-05-19 |
| Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome Ibrutinib, Lenalidomide - Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome | Phase 1 | Completed | University of California, Davis | 4 | 2017-12-01 | 2026-03-10 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Blinatumomab, Lenalidomide - Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2016-11-15 | 2025-11-26 |
| A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Durvalumab, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Celgene | 56 | 2016-04-25 | 2023-10-06 |
| Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide - Recurrent Plasma Cell Myeloma | Phase 1 | Completed | Mayo Clinic | 10 | 2016-04-14 | 2023-12-28 |
| Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma Anakinra, Dexamethasone, Laboratory Biomarker Analysis - Indolent Plasma Cell Myeloma, Plasma Cell Myeloma | Phase 1 | Completed | Mayo Clinic | 14 | 2016-04-01 | 2020-03-25 |
| Treatment of IgG4-Related Disease With Revlimid and Rituximab Rituximab, Lenalidomide - Immunoglobulin G Subclass 4 Related Disease, IgG4-related Disease | Phase 1 | Completed | Mayo Clinic | 6 | 2016-04-01 | 2019-07-08 |
| Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma Elotuzumab, Lenalidomide, autologous PBMC reconstitution - Multiple Myeloma | Phase 1 | Completed | Hearn Jay Cho | 15 | 2016-01-01 | 2017-08-18 |
| A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma Lenalidomide, Obinutuzumab, Cyclophosphamide - Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 59 | 2015-11-04 | 2024-09-19 |
| Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation lenalidomide, bortezomib, cyclophosphamide - Plasma Cell Myeloma | Phase 1 | Completed | Sanofi | 90 | 2015-09-30 | 2024-01-29 |
| Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Doxorubicin Hydrochloride - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 1 / Phase 2 | Completed | University of Nebraska | 54 | 2015-09-28 | 2023-12-13 |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma Lenalidomide, Rituximab, Fludarabine - Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 8 | 2015-03-05 | 2023-06-07 |
| Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation Lenalidomide, Velcade - Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 | Completed | Massachusetts General Hospital | 22 | 2015-02-01 | 2026-01-16 |
| Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients Melphalan, Prednisone, Cyclophosphamide - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Oncotherapeutics | 45 | 2014-09-01 | 2023-10-31 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
Showing 20 of 96. Sign in to see all of them.
Multiple Myeloma (31) · Leukemia, Lymphocytic, Chronic, B-Cell (16) · Lymphoma, Follicular (10) · Lymphoma, Mantle-Cell (10) · Lymphoma, B-Cell, Marginal Zone (9) · Leukemia, Myeloid, Acute (8) · Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Non-Hodgkin (7) · Recurrence (7) · Myelodysplastic Syndromes (6) · Neoplasms, Plasma Cell (6) · Waldenstrom Macroglobulinemia (6) · Hodgkin Disease (5) · Leukemia (5) · Lymphoma (5)
M.D. Anderson Cancer Center (11) · National Cancer Institute (NCI) (11) · Mayo Clinic (5) · Massachusetts General Hospital (3) · University of Nebraska (3) · Arbeitsgemeinschaft medikamentoese Tumortherapie (2) · Celgene (2) · Dana-Farber Cancer Institute (2) · Emory University (2) · SCRI Development Innovations, LLC (2) · Sanofi (2) · Seagen Inc. (2) · University of California, Davis (2) · Washington University School of Medicine (2) · Alliance Foundation Trials, LLC. (1)
United States (77) · Germany (6) · France (5) · Canada (3) · Spain (3) · Austria (2) · Italy (2) · Switzerland (2) · Australia (1) · Belgium (1) · Denmark (1) · Finland (1) · Greece (1) · Netherlands (1) · Sweden (1)
Joseph M Tuscano (2) · Sonali Smith (2) · Agop Y. Bedikian, MD (1) · Ajay Nooka, MD (1) · Andrew M Brunner, MD (1) · Apostolia M. Tsimberidou, MD, PhD (1) · Brian Jonas (1) · Bruce D Cheson, MD (1) · Bruno Carneiro de Medeiros (1) · Carlos de Castro, MD (1) · Chih-Yi Liao (1) · Chitra M. Hosing, MD (1)
PMID 18824593, PMID 19182205, PMID 19965642, PMID 20724537, PMID 21149673, PMID 21596852, PMID 21816833, PMID 22033493, PMID 22517904, PMID 22936658, PMID 23100308, PMID 23242596, PMID 23592273, PMID 23756764, PMID 23834234, PMID 24004667, PMID 24562384, PMID 25082342, PMID 25837499, PMID 26058589, PMID 26284823, PMID 26331432, PMID 26643449, PMID 26687423, PMID 27018242, PMID 27646843, PMID 27872060, PMID 28099502, PMID 28483761, PMID 29296805, PMID 29802551, PMID 29862437, PMID 29986852, PMID 30068505, PMID 30128502, PMID 30501870, PMID 31296423, PMID 31723767, PMID 32704173, PMID 33357482, PMID 34272304, PMID 34320785, PMID 34936697, PMID 34955443, PMID 35247913, PMID 36375046, PMID 37316728, PMID 38609316, PMID 39161543, PMID 39321347
U01CA076576 (4), P30CA014599 (3), 2009 (2), N01CM00071 (2), N01CM62201 (2), P30CA016058 (2), P30CA036727 (2), P30CA093373 (2), UM1CA186712 (2), 2008 (1), 2014 (1), 2015 (1), N01CM00032 (1), N01CM00038 (1), N01CM00099 (1)